Pediatric oncologists are increasingly choosing immunotherapy as a first-line treatment because landmark clinical trials now show it dramatically reduces relapse while sparing children the devastating long-term side effects of conventional chemotherapy and radiation. The clearest example came from the AALL1731 trial, which enrolled more than 1,400 children ages one to ten with newly diagnosed standard-risk B-cell acute lymphoblastic leukemia. Adding blinatumomab to standard chemotherapy improved three-year disease-free survival to 96 percent, compared with 87.9 percent for chemotherapy alone — a 61 percent reduction in relapse events. Those results, published in the New England Journal of Medicine and presented at the American Society of Hematology annual meeting in December, are expected to make blinatumomab part of standard initial treatment for many children with ALL.
The shift is not just about better cure rates. Between 60 and over 90 percent of childhood cancer survivors treated with traditional chemotherapy and radiation develop one or more chronic health conditions later in life, including cardiac damage, pulmonary disease, endocrine dysfunction, reproductive problems, neurocognitive disorders, impaired growth, and second cancers. Immunotherapies work through fundamentally different mechanisms than DNA-damaging drugs, and they exhibit fewer and different long-term toxicities. For pediatric oncologists — who must think not just about curing cancer but about the sixty or seventy years of life that follow — that tradeoff is becoming impossible to ignore. This article covers the specific immunotherapy agents now approved or in trials for childhood cancers, the clinical data behind the shift toward first-line use, what the known limitations and risks are, and how new research is expanding the list of children who may benefit.
Table of Contents
- What Is Driving Pediatric Oncologists to Choose Immunotherapy Before Traditional Chemotherapy?
- Which Immunotherapy Agents Are FDA-Approved for Children, and What Are Their Limitations?
- How CAR-T Cell Therapy Is Reshaping Outcomes for Children with Leukemia
- Long-Term Survivorship and the Tradeoff Between Cure and Quality of Life
- Where Immunotherapy Still Falls Short in Pediatric Cancer
- New Research Is Expanding the Map of Immunotherapy Targets in Childhood Cancer
- What the Next Five Years Could Look Like for Pediatric Cancer Immunotherapy
- Conclusion
- Frequently Asked Questions
What Is Driving Pediatric Oncologists to Choose Immunotherapy Before Traditional Chemotherapy?
The core argument is straightforward: if an immunotherapy can match or exceed the cancer-killing effectiveness of intensive chemotherapy while causing less collateral damage to a growing body, it should be used earlier rather than saved as a last resort. For decades, immunotherapy agents were reserved for children who had already relapsed or failed multiple rounds of treatment. that made sense when the evidence base was thin. It no longer does. The AALL1731 data showed that blinatumomab — a bispecific T-cell engager that directs the patient’s own immune cells to attack leukemia — works not just in relapsed disease but as part of initial therapy, and works better than chemotherapy intensification alone.
The same logic has played out in neuroblastoma. Dinutuximab, an anti-GD2 antibody, was FDA-approved in 2015 for high-risk neuroblastoma after a phase III trial demonstrated five-year event-free survival of 56.6 percent for the immunotherapy arm versus 46.1 percent for isotretinoin alone, with five-year overall survival of 73.2 percent compared to 56.6 percent. Dinutuximab is now a standard component of frontline treatment, not a salvage option. The pattern is consistent: once the trial data supports moving immunotherapy earlier, oncologists adopt it, because the combination of better efficacy and a more tolerable side-effect profile is a clear win for a population that has an entire lifetime ahead. Compare this to the trajectory in adult oncology, where checkpoint inhibitors moved from last-line to first-line treatment for lung cancer and melanoma over a span of roughly five years once key trials reported. Pediatric oncology is following the same arc, though with different agents suited to the biology of childhood cancers.
Which Immunotherapy Agents Are FDA-Approved for Children, and What Are Their Limitations?
There are currently five or more FDA-approved immunotherapy options for childhood cancer. Blinatumomab, a bispecific antibody, is approved for B-cell ALL. Dinutuximab targets GD2 in neuroblastoma. Tisagenlecleucel, a CD19-targeted CAR-T cell therapy, is approved for patients 25 years and younger with relapsed or refractory B-ALL. Pembrolizumab, a checkpoint inhibitor, is approved for children with refractory classical Hodgkin lymphoma after three or more prior lines of therapy and for solid tumors with high tumor mutational burden — at least ten mutations per megabase — under an accelerated approval granted on June 16, 2020. Rituximab, an anti-CD20 antibody, is used in certain pediatric leukemias and lymphomas. However, approval does not mean universal applicability.
Checkpoint inhibitors like pembrolizumab have shown response rates of 30 to 60 percent in pediatric relapsed Hodgkin lymphoma, which is meaningful but far from a guaranteed cure. Most common pediatric solid tumors — including neuroblastoma, Wilms tumor, and many sarcomas — have low tumor mutational burden and limited neoantigen expression, which means checkpoint inhibitors alone are often ineffective against them. The TMB-high approval covers a real but relatively narrow slice of pediatric solid tumors. Oncologists cannot simply substitute pembrolizumab for chemotherapy in most childhood cancers and expect it to work. The toxicity profile also varies by agent. Dinutuximab causes significant pain during infusion and can trigger capillary leak syndrome. CAR-T therapy carries the risk of cytokine release syndrome and prolonged B-cell depletion requiring immunoglobulin replacement. These are manageable side effects, but they are not trivial, and families need honest counseling about what “less toxic than chemotherapy” actually means in practice for each specific drug.
How CAR-T Cell Therapy Is Reshaping Outcomes for Children with Leukemia
Tisagenlecleucel became a landmark when the ELIANA trial demonstrated an 81 percent complete remission rate in children and young adults with relapsed or refractory B-ALL — a population that historically had very few options and dismal outcomes. Overall survival at 12 months was 76 percent. For a group of patients who had already failed standard chemotherapy, those numbers represented something close to a revolution. What makes CAR-T particularly compelling for pediatric use is the emerging evidence on long-term toxicity. Cytokine release syndrome, the most feared acute side effect, is now well understood and treatable with tocilizumab and corticosteroids. B-cell depletion is a known consequence of targeting CD19, but it is manageable with regular immunoglobulin infusions.
Critically, the long-term late effects of CAR-T therapy appear less severe than those of allogeneic stem cell transplantation, which has historically been the main alternative for children who relapse. Transplant carries risks of graft-versus-host disease, organ damage, infertility, and secondary malignancies that can shadow a survivor for decades. The next generation of CAR-T is already in development. Multi-targeted constructs — such as those hitting both CD19 and CD22 simultaneously — aim to prevent the antigen escape that causes some children to relapse after initial CAR-T therapy. So-called armored CAR-T cells, engineered with enhanced cytokine signaling, are designed to persist longer and function better in the hostile tumor microenvironment. For children with T-cell ALL, which cannot be treated with CD19-directed therapies, new CAR-T cells targeting CD5 and CD7 are showing significant response rates in early trials. These advances suggest the role of CAR-T in pediatric cancer will expand considerably over the next several years.
Long-Term Survivorship and the Tradeoff Between Cure and Quality of Life
The 87 percent five-year survival rate for children diagnosed with cancer — based on 2015 to 2021 data — is rightly celebrated as one of modern medicine’s great achievements. All-cause mortality among childhood cancer survivors has declined from 10.7 percent to 5.8 percent over recent decades. But those numbers mask a difficult reality: surviving childhood cancer with conventional treatment often means living with its consequences for decades. The American Cancer Society reports that 60 to over 90 percent of childhood cancer survivors develop at least one chronic health condition attributable to their treatment. Anthracycline chemotherapy damages the heart. Cranial radiation impairs cognitive development. Alkylating agents cause infertility.
Radiation to the chest increases the risk of breast cancer in female survivors. These are not rare complications — they are the expected outcome for most survivors of intensive treatment protocols. A child cured of leukemia at age five may face heart failure in her thirties, cognitive difficulties that limit her education, or a second cancer before age forty. This is why the long-term toxicity argument carries so much weight in pediatric oncology. If blinatumomab can replace a cycle of intensive chemotherapy and achieve equal or better disease control, every avoided dose of anthracycline is a potential decade of healthier cardiac function. If CAR-T can substitute for a stem cell transplant, the child avoids chronic graft-versus-host disease and its cascade of complications. The calculus is different from adult oncology, where patients may have twenty or thirty years of expected life remaining. For a five-year-old, the treatment decisions made today will shape health outcomes into the 2080s.
Where Immunotherapy Still Falls Short in Pediatric Cancer
Despite the momentum, immunotherapy is not a universal solution for childhood cancer, and overstating its promise does patients no favors. The majority of pediatric solid tumors — osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and most brain tumors — remain largely resistant to currently available immunotherapies. These cancers tend to have low mutational burdens, immunosuppressive tumor microenvironments, and limited surface antigen targets that current agents can exploit. Brain tumors are a particular challenge. They account for the leading cause of cancer death in children, yet the blood-brain barrier limits drug delivery, and the central nervous system is an immunologically privileged site where immune responses are naturally dampened. Checkpoint inhibitors have shown limited efficacy in pediatric brain tumors to date, and CAR-T delivery to the brain remains experimental.
Some early-phase trials are exploring direct intrathecal or intracavitary delivery of CAR-T cells, but these approaches are years from becoming standard. There is also the issue of access and cost. CAR-T therapy requires specialized manufacturing for each patient, takes weeks to produce, and costs several hundred thousand dollars per treatment. Not every pediatric cancer center can administer it. Insurance coverage battles remain common. For families outside major academic medical centers, the logistical and financial barriers to accessing cutting-edge immunotherapy can be formidable, even when the clinical evidence supports its use.
New Research Is Expanding the Map of Immunotherapy Targets in Childhood Cancer
In February 2026, scientists at the Hudson Institute of Medical Research in Australia published a first-of-its-kind catalog that used artificial intelligence to analyze more than 200 high-risk pediatric cancer cell lines, identifying HLA profiles that could reveal new immunotherapy targets. The work builds on the Childhood Cancer Model Atlas, which has served as the largest open-source repository of pediatric cancer tissue samples in the world since its launch in 2023. By systematically mapping the antigen landscape of childhood cancers, this research aims to identify targets for new immunotherapy agents — particularly for tumor types that have not yet benefited from existing drugs.
This kind of systematic target discovery matters because the current immunotherapy toolkit for pediatric cancer is still small. Five approved agents is a start, but adult oncology has dozens. Expanding the target catalog is the prerequisite for expanding the drug pipeline, and open-source efforts like the Childhood Cancer Model Atlas accelerate that process by making data available to researchers worldwide rather than locking it behind institutional walls.
What the Next Five Years Could Look Like for Pediatric Cancer Immunotherapy
The trajectory points toward immunotherapy becoming a standard component of first-line treatment for most common childhood cancers within the next five to ten years, though the pace will vary by tumor type. ALL is farthest along, with blinatumomab poised to enter standard protocols imminently based on the AALL1731 results. Neuroblastoma already incorporates dinutuximab as standard of care.
For Hodgkin lymphoma, the question is no longer whether checkpoint inhibitors work in children but how early they can be moved into the treatment sequence to reduce the radiation and chemotherapy burden. The harder frontier is pediatric solid tumors and brain tumors, where the biological barriers are more formidable. Progress here will likely depend on advances in CAR-T engineering, bispecific antibodies targeting novel surface antigens, and combination strategies that pair immunotherapy with agents that remodel the tumor microenvironment. The AACR’s 2025 Pediatric Cancer Progress Report underscores that immunotherapies exhibit fewer and different long-term toxicities compared to DNA-damaging chemotherapy — a finding that will continue to motivate the push toward earlier use as new agents prove themselves in trials.
Conclusion
Pediatric oncologists are choosing immunotherapy first because the evidence now supports it. The AALL1731 trial showed that adding blinatumomab to frontline chemotherapy for standard-risk childhood ALL cut relapse by 61 percent and pushed three-year disease-free survival to 96 percent. CAR-T therapy achieves 81 percent complete remission in relapsed B-ALL with a side-effect profile less damaging than transplant. Dinutuximab has been standard of care for high-risk neuroblastoma since 2015. The common thread is better disease control with fewer of the chronic health problems that plague survivors of conventional treatment — problems that affect 60 to over 90 percent of those treated with traditional approaches. The shift is not complete, and it is not without caveats.
Many pediatric tumor types remain resistant to current immunotherapies. Access and cost barriers persist. The toxicities of these newer agents, while generally less severe than chemotherapy, are real and require experienced management. But the direction is unmistakable. As the target landscape expands through efforts like the Hudson Institute catalog and the Childhood Cancer Model Atlas, and as next-generation CAR-T constructs address current limitations, immunotherapy’s role in frontline pediatric cancer treatment will only grow. For families facing a childhood cancer diagnosis, the question to ask the oncology team is increasingly not whether immunotherapy is an option, but where it fits in the treatment plan.
Frequently Asked Questions
What is blinatumomab, and why is it significant for childhood leukemia?
Blinatumomab is a bispecific T-cell engager antibody that directs the patient’s own T cells to attack cancer cells expressing CD19, a protein found on B-cell leukemia. The AALL1731 trial showed that adding it to standard chemotherapy for newly diagnosed standard-risk childhood ALL improved three-year disease-free survival from 87.9 percent to 96 percent, making it the first immunotherapy agent expected to enter standard first-line protocols for this common childhood cancer.
Is CAR-T cell therapy safe for children?
CAR-T therapy carries real risks, including cytokine release syndrome and prolonged B-cell depletion, but these side effects are well characterized and manageable with current supportive care. The ELIANA trial of tisagenlecleucel showed an 81 percent complete remission rate in children with relapsed B-ALL. Importantly, the long-term late effects of CAR-T appear less severe than those of allogeneic stem cell transplantation, which has historically been the main alternative for relapsed patients.
Why are long-term side effects such a major factor in choosing pediatric cancer treatments?
Because children who survive cancer may live sixty or seventy more years, and 60 to over 90 percent of survivors treated with conventional chemotherapy and radiation develop chronic health conditions including heart damage, cognitive impairment, infertility, and second cancers. Immunotherapies work through different mechanisms than DNA-damaging drugs and appear to cause fewer of these lasting problems, which is why oncologists are motivated to use them earlier.
Do checkpoint inhibitors like pembrolizumab work in all childhood cancers?
No. Pembrolizumab is FDA-approved for children with refractory Hodgkin lymphoma and for solid tumors with high tumor mutational burden, but most common pediatric solid tumors have low mutational burdens and respond poorly to checkpoint inhibition alone. Its use in pediatric cancer remains limited to specific indications where the biology supports an immune response.
How many immunotherapy drugs are currently approved for children with cancer?
There are five or more FDA-approved immunotherapy options for pediatric cancer: blinatumomab for ALL, dinutuximab for neuroblastoma, tisagenlecleucel (CAR-T) for B-ALL, pembrolizumab for Hodgkin lymphoma and TMB-high solid tumors, and rituximab for certain leukemias and lymphomas. This number is expected to grow as clinical trials of new agents report results.
What new research is being done to find more immunotherapy targets for childhood cancer?
In February 2026, researchers at the Hudson Institute of Medical Research in Australia published a catalog using artificial intelligence to analyze over 200 high-risk pediatric cancer cell lines, identifying HLA profiles that could point to new immunotherapy targets. This work builds on the Childhood Cancer Model Atlas, the world’s largest open-source repository of pediatric cancer tissue samples, and aims to expand the range of childhood cancers that can be treated with immunotherapy.
